A cell therapy is under development for progressive multiple sclerosis (MS) patients with ongoing inflammatory tissue injury and who are HLA-DRB1*15:01 positive.
GT201, a novel therapy, previously received IND clearance from China’s Center for Drug Evaluation in July 2023, marking a significant regulatory milestone.
Data from the pivotal part B cohort of the phase 2/3 DEVOTE clinical trial demonstrated an 85% median reduction in HS D2S6 levels in the CSF among patients receiving the pivotal dose.
Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.
Get curated, high-impact pharmaceutical news delivered to your inbox every morning.